Best GLP-1 peptide in 2026: a clear ranking of semaglutide, tirzepatide, and retatrutide
All three GLP-1 peptides reduce body weight, but they don't perform identically. Here's a clear ranking by goal, access, and side effects.
by Editorial team
Ranking by average weight loss
Retatrutide (~24% at highest dose, phase 2) > tirzepatide (~22% over 72w) > semaglutide (~15% over 68w). These numbers are averages — individual response varies meaningfully.
Ranking by access and predictability
Semaglutide is the most established with the longest real-world safety record. Tirzepatide is well-established with strong trial data and broad availability in most countries. Retatrutide is still trial-only and not generally accessible outside research peptide channels.
How to actually choose
Default to semaglutide if cost or access is tight and weight loss goals are moderate. Move to tirzepatide if semaglutide stalls or your goals require deeper weight loss. Reserve retatrutide for after approval unless you're working with a clinician who's tracking the trial landscape closely.